Shengjiyuhong ointment inhibits hypertrophic scar formation

doi:10.3969/j.issn.2095-4344.2016.33.004

Abstract

Abstract:

BACKGROUND: Shengjiyuhong ointment has been reported to inhibit hypertrophic scarring.
OBJECTIVE: To verify the effects of Shengjiyuhong ointment on hypertrophic scarring of in a rabbit ear model.
METHODS: Each ear of thirty-six Japanese rabbits was used to make four 1-cm-diameter circular full-thickness skin wounds with the entire perichondrium removed. Finally, 288 wounds were made and randomly divided into 6 groups: model, negative control (no drugs were administered), low-, moderate-, high-crude herbal dose drugs (Shengjiyuhong ointment was administered topically at concentrations of 8.39%, 25.18%, and 75.54%), and positive control (recombinant bovine basic fibroblast growth factor was administered topically). Shengjiyuhong ointment was administered twice daily till wound healing. The wounds were evaluated by the Vancouver scar scale (VSS). Scar elevation index (SEI) of scar specimens was calculated under a microscope at 40× magnification. mRNA expression levels of type I and III collagen, connective tissue growth factor, fibronectin, and α-smooth muscle actin (α-SMA) were determined by fluorescent quantitative PCR. Protein expression levels of type I and III collagen and α-SMA were detected by western blot assay. α-SMA immunoreactivity was determined by immunofluorescent staining.
RESULTS AND CONCLUSION: VSS scores and SEI were significantly increased in each group at 30 days (P < 0.05). VSS scores and SEI were significantly decreased in the moderate- and high-crude herbal dose drug groups and positive control groups compared with the model, negative control, and low-crude herbal dose drug groups (P < 0.05 or P < 0.01). mRNA expression levels of type I and III collagen, connective tissue growth factor and fibronectin, and protein expression levels of type I and III collagen and α-SMA were significantly inhibited after moderate-crude herbal dose Shengjiyuhong ointment and positive drug treatment (P < 0.01). These findings suggest that Shengjiyuhong ointment can reduce hypertrophic scars by inhibiting fibroblast proliferation and collagen deposition.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Drugs, Chinese Herbal, Cicatrix, Collagen Type I, Collagen Type III

CLC Number:

R318

Sun Gui-fang, Zhang Xiao-fen, Li Hong-chang, Pan Li-yun, Chen Ya-feng, Xu Ke, Feng Dian-xu. Shengjiyuhong ointment inhibits hypertrophic scar formation[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(33): 4890-4898.

Figures/Tables 5

References

[1] Fearmonti R, Bond J, Erdmann D, et al. A review of scar scales and scar measuring devices.Eplasty. 2010; 21;10:e43.
[2] Zhu Z, Ding J, Shankowsky HA, et al. The molecular mechanism of hypertrophic scar.J Cell Commun Signal. 2013;7(4): 239-252.
[3] Li B, Wang JH-C.Fibroblasts and myofibroblasts in wound healing: Force generation and measurement. J Tissue Viability. 2011; 20(4):108-120.
[4] Sarrazy V, Billet F, Micallef L, et al.Mechanisms of pathological scarring: role of myofibroblasts and current developments.Wound Repair Regen. 2011; 19(s1): s10-s15.
[5] Hinz B,Phan SH,Thannickal VJ,et al.Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.The American journal of pathology.2012;180(4): 1340-1355.
[6] Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins.Am J Pathol. 2007;170(6):1807-1816.
[7] Wang YW, Liou NH, Cherng JH,et al.siRNA-Targeting Transforming Growth Factor-β Type I Receptor Reduces Wound Scarring and Extracellular Matrix Deposition of Scar Tissue.J Invest Dermatol. 2014; 134(7):2016-2025.
[8] Arno AI, Gauglitz GG, Barret JP, et al. Up-to-date approach to manage keloids and hypertrophic scars: A useful guide.Burns.2014;40(7): 1255-1266.
[9] 安凤敏.生肌玉红膏修复压疮减少瘢痕形成39例报告[J].中国临床康复, 2002,6(4): 546.
[10] 缪雪华,张宇轩,陈运,等.生肌玉红胶原海绵促进胶原合成与组织愈合的研究[J].南京中医药大学学报, 2012,28(4): 337-341.
[11] 周勇.生肌玉红膏促进慢性下肢溃疡创面肉芽生长临床与实验研究[D]: 南京中医药大学, 2012.
[12] 赵春霖,王丽娟,董小鹏,等.生肌玉红膏对深Ⅱ度烧伤大鼠创面愈合过程中Ⅰ, Ⅲ 型胶原表达变化的影响[J].中国中医药科技, 2013,20(5): 467-468.
[13] 张艳, 荆玉洁.生肌玉红膏保守治疗腹切口不完全裂开的疗效[J].中国实用医药, 2015,10(23): 177-178.
[14] 杨志光.复元活血汤联合生肌玉红膏治疗糖尿病足的临床观察[J].陕西中医, 2015,36(9): 1176-1177.
[15] 杨澔侠,高卫卫,姚昶,等.生肌玉红膏胶原海绵对创面胶原塑形的影响及机制[J]. 山东医药, 2011,51(31): 10-12.
[16] 曹东阳,姚昶,陈德轩,等.皮下植入生肌玉红胶原后的血管新生与瘢痕抑制[J].中国组织工程研究, 2013,17(34): 6144-6151.
[17] 张雪.六物消瘢膏治疗皮肤病理性瘢痕的临床观察及实验研究[D]:山东中医药大学, 2014.
[18] 刘凯,张选奋,张瑾,等.当归挥发油对增生性瘢痕成纤维细胞增殖,凋亡及胶原合成的影响[J].中国美容医学, 2012, 21(9):1536-1538.
[19] 彭旦明,蔡紫光,张瑾楠,等.紫草素对增生性瘢痕中 VEGF亚型mRNA表达的影响[J].实用中西医结合临床, 2010(2):1-2.
[20] 彭旦明,汪华,刘雯,等.紫草色素对兔耳增生性瘢痕的影响[J].四川中医,2011,29(4): 54-58.
[21] 李靖,张飞,陈曦,等.紫草油提取物对小鼠瘢痕的抑制作用[J].中西医结合研究, 2009,1(2): 72-74.
[22] Bai X, He T, Liu J, et al. Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-beta/Smad pathway. Exp Dermatol.2015;24(5): 355-360.
[23] 赵丽,周晓宏,关洪全.黑布药膏对兔耳增生性瘢痕胶原合成与降解的影响[J].中国实验方剂学杂志, 2011,17(14): 215-218.
[24] Morris D, Wu L, Zhao L, et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg. 1997;100(3): 674-681.
[25] Shi HX, Lin C, Lin BB, et al. The anti-scar effects of basic fibroblast growth factor on the wound repair in vitro and in vivo. PLoS One. 2013;8(4): e59966.
[26] Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:123-135.
[27] Van De Water L, Varney S, Tomasek JJ. Mechanoregulation of the myofibroblast in wound contraction, scarring, and fibrosis: opportunities for new therapeutic intervention. Advances in Wound Care, 2013,2(4): 122-141.
[28] 刘德伍,苏子毅.当归对兔耳增生性瘢痕的治疗作用[J]. 中药药理与临床, 1998,14(6): 30-31.
[29] 朱桂英,徐斌,蔡景龙.兔耳解剖特点与成功建立增生性瘢痕模型的相关性实验研究[J].中华整形外科杂志, 2008, 24(3):216-219.
[30] 邱恒,孙新民,黄雯,等.玉红膏重复给药大鼠体内汞的吸收及蓄积研究[J].中国中药杂志, 2013,38(6): 884-888.
[31] Arno AI, Gauglitz GG, Barret JP, et al. New molecular medicine-based scar management strategies.Burns. 2014;40(4):539-551.
[32] Leask A,Abraham DJ.TGF-β signaling and the fibrotic response.FASEB J. 2004;18(7):816-827.